Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price traded up 4.8% during trading on Monday . The stock traded as high as $15.10 and last traded at $14.71. 13,145 shares changed hands during trading, a decline of 60% from the average session volume of 33,229 shares. The stock had previously closed at $14.03.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $29.20.
Check Out Our Latest Report on OCS
Oculis Stock Down 4.6 %
Oculis (NASDAQ:OCS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. As a group, research analysts forecast that Oculis Holding AG will post -2.19 EPS for the current year.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
- Five stocks we like better than Oculis
- Investing in Commodities: What Are They? How to Invest in Them
- Short Sellers Eye Palantir: Should You Buy the Dip?
- What are earnings reports?
- Is This NVIDIA Backed Robotics Stock a Buy As It Nears Expansion?
- The Risks of Owning Bonds
- Bet on These 3 High-Yield Stocks as Natural Gas Demand Grows
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.